Better Medicines for Rare Diseases: Fighting Hidden Bias in Health Decisions

How are life-saving treatments chosen? When governments decide which medicines to evaluate, they often overlook rare diseases. Most health plans focus on treatments that help large groups, leaving small patient communities behind. Rare disease drugs, called orphan medicinal products, rarely get fair consideration simply because they affect few people. Three big problems stand in the way. First, health agencies usually work in closed rooms without input from patients. Second, they judge value mostly by how many people a treatment could help rather than how badly those people need it. Third, patients with rare diseases almost never sit at the table where decisions are made. A drug for 1 in a thousand still matters—but not if no one speaks for it.New decision-making tools exist that could shift this balance. Some systems ask not only “Does this treatment work? ” but “Is this treatment fair? ” Others weigh different values—like giving a chance to those who have no other options. However, many agencies haven’t put these ideas into practice. Rules exist, but they aren’t used consistently. What could make a difference? Systems that scan the horizon for promising rare disease treatments early could help. Allowing anyone to suggest a treatment—even patients or caregivers—could open doors that were once closed. Some countries already have special fast-track rules for rare disease drugs. These policies show that change is possible when leaders decide to act. But real progress needs more than new forms and checklists. It needs a mindset shift: valuing every life equally, even when some voices are quieter.